{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-040703","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.262605+00:00","generated_at":"2026-05-15T06:52:48.202141+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12","bullets":["Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.","First participant dosing expected in second quarter 2026.","IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass in obesity, with potential for 2-4 doses per year.","Series G warrants (outstanding ~27.9M shares) will expire on May 12, 2026 – 30 trading days after this public announcement.","If all Series G warrants exercised, an additional ~27.9M common shares issued plus Series H warrants for same amount."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-040703","json":"https://secwatch.observer/filing/0001104659-26-040703.json","markdown":"https://secwatch.observer/filing/0001104659-26-040703.md","text":"https://secwatch.observer/filing/0001104659-26-040703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/0001104659-26-040703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/ibio-20260408x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:52:48.202141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}